SEC Company Response from China Medical Technologies, Inc. (CIK 0001326059) — Aug 5, 2005
China Medical Technologies, Inc. (CIK 0001326059)
Date: Aug. 5, 2005 · CIK: 0001326059 · Accession: 0001193125-05-159032
AI Filing Summary & Sentiment
File numbers found in text: 000-51440, 333-126630
Letter
Via Edgar and Facsimile Securities and Exchange Commission Division of Corporation Finance Attention: Mr. Russell Mancuso, Branch Chief Mr. Donald C. Hunt, Attorney Advisor Re: China Medical Technologies, Inc. Registration Statement on Form F-1 (Registration No. 333-126630) Registration Statement on Form 8-A (Registration No. 000-51440)
Dear Messrs. Mancuso and Hunt:
Pursuant to Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, China Medical Technologies, Inc. (the “Company”) hereby requests that the effective date of the above-referenced Registration Statement on Form F-1 be accelerated to, and that such Registration Statement be declared effective on, August 9, 2005 at 2:00 pm, New York Time, or as soon thereafter as practicable, unless we or our US counsel, Latham & Watkins LLP, requests by telephone that such Registration Statement be declared effective at some other time.
The Company also requests that the Registration Statement on Form 8-A under the Securities Exchange Act of 1934, as amended, covering the American depositary shares representing ordinary shares of the Company be declared effective concurrently with the above-captioned Registration Statement on F-1.
The Company hereby acknowledges the following:
•
should the Securities and Exchange Commission (the “Commission”) or the staff of the Commission (the “Staff”), acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
•
the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
•
the Company may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
(Signature Page to Follow)
Very truly yours,
China Medical Technologies, Inc.
Show Raw Text
CORRESP 1 filename1.htm SEC Letter China Medical Technologies, Inc. No. 24 Yong Chang North Road Beijing Economic-Technological Development Area Beijing 100176, People’s Republic of China August 5, 2005 Via Edgar and Facsimile Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Mr. Russell Mancuso, Branch Chief Mr. Donald C. Hunt, Attorney Advisor Re: China Medical Technologies, Inc. Registration Statement on Form F-1 (Registration No. 333-126630) Registration Statement on Form 8-A (Registration No. 000-51440) Dear Messrs. Mancuso and Hunt: Pursuant to Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, China Medical Technologies, Inc. (the “Company”) hereby requests that the effective date of the above-referenced Registration Statement on Form F-1 be accelerated to, and that such Registration Statement be declared effective on, August 9, 2005 at 2:00 pm, New York Time, or as soon thereafter as practicable, unless we or our US counsel, Latham & Watkins LLP, requests by telephone that such Registration Statement be declared effective at some other time. The Company also requests that the Registration Statement on Form 8-A under the Securities Exchange Act of 1934, as amended, covering the American depositary shares representing ordinary shares of the Company be declared effective concurrently with the above-captioned Registration Statement on F-1. The Company hereby acknowledges the following: • should the Securities and Exchange Commission (the “Commission”) or the staff of the Commission (the “Staff”), acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; • the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and • the Company may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. (Signature Page to Follow) Very truly yours, China Medical Technologies, Inc. By: /s/ Xiaodong Wu Name: Xiaodong Wu Title: Chairman and Chief Executive Officer